Shandong Realcan Pharmaceutical Co Ltd (002589) — Net Asset Quality Index
Shandong Realcan Pharmaceutical Co Ltd (002589) has a Net Asset Quality Index of 35.0% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥15.55 Billion minus total liabilities of CN¥10.10 Billion yields net assets of CN¥5.44 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See Shandong Realcan Pharmaceutical Co Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Shandong Realcan Pharmaceutical Co Ltd Net Asset Quality Index Over Time (2008–2025)
This chart shows how Shandong Realcan Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 18 annual periods from 2008 to 2025. As of March 2026, the index stands at 35.0%, representing net assets of CN¥5.44 Billion against total assets of CN¥15.55 Billion CNY. Explore cash flow conversion of Shandong Realcan Pharmaceutical Co Ltd to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Shandong Realcan Pharmaceutical Co Ltd (2008–2025)
The table below presents the year-by-year Net Asset Quality Index for Shandong Realcan Pharmaceutical Co Ltd from 2008 to 2025, covering 18 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market cap of Shandong Realcan Pharmaceutical Co Ltd.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 37.7% | CN¥5.42 Billion | CN¥14.37 Billion | CN¥8.95 Billion | ▲ +2.2 pp |
| 2024 | 35.6% | CN¥5.69 Billion | CN¥16.01 Billion | CN¥10.32 Billion | ▲ +1.8 pp |
| 2023 | 33.7% | CN¥5.64 Billion | CN¥16.71 Billion | CN¥11.07 Billion | ▲ +2.4 pp |
| 2022 | 31.4% | CN¥5.75 Billion | CN¥18.33 Billion | CN¥12.58 Billion | ▼ -5.3 pp |
| 2021 | 36.7% | CN¥9.69 Billion | CN¥26.40 Billion | CN¥16.70 Billion | ▲ +5.9 pp |
| 2020 | 30.8% | CN¥9.64 Billion | CN¥31.29 Billion | CN¥21.65 Billion | ▼ -0.8 pp |
| 2019 | 31.6% | CN¥10.25 Billion | CN¥32.47 Billion | CN¥22.21 Billion | ▼ -0.9 pp |
| 2018 | 32.5% | CN¥11.31 Billion | CN¥34.84 Billion | CN¥23.53 Billion | ▼ -3.4 pp |
| 2017 | 35.9% | CN¥9.67 Billion | CN¥26.98 Billion | CN¥17.31 Billion | ▼ -12.1 pp |
| 2016 | 47.9% | CN¥7.50 Billion | CN¥15.66 Billion | CN¥8.15 Billion | ▲ +9.5 pp |
| 2015 | 38.4% | CN¥3.40 Billion | CN¥8.86 Billion | CN¥5.46 Billion | ▲ +6.3 pp |
| 2014 | 32.1% | CN¥1.83 Billion | CN¥5.68 Billion | CN¥3.85 Billion | ▼ -4.9 pp |
| 2013 | 37.0% | CN¥1.65 Billion | CN¥4.45 Billion | CN¥2.80 Billion | ▲ +7.7 pp |
| 2012 | 29.4% | CN¥916.39 Million | CN¥3.12 Billion | CN¥2.20 Billion | ▼ -7.5 pp |
| 2011 | 36.8% | CN¥817.11 Million | CN¥2.22 Billion | CN¥1.40 Billion | ▲ +16.8 pp |
| 2010 | 20.0% | CN¥296.03 Million | CN¥1.48 Billion | CN¥1.18 Billion | ▼ -2.5 pp |
| 2009 | 22.5% | CN¥234.18 Million | CN¥1.04 Billion | CN¥805.78 Million | ▲ +6.9 pp |
| 2008 | 15.6% | CN¥111.89 Million | CN¥715.53 Million | CN¥603.64 Million | — |